Amarin Corp Plc (AMRN)

[HDGabor]

"the trial results are being monitored every three months. If the results show an unanticipated large percentage of reduction in events, the monitors have the option to stop the study"

In this case, yes it could be within 12 / 18 months, however we never got a positive "answer" for any open issue (SPA, NCE, etc.)

During the last 6 months I go through again and again on all info, docs, etc. and I still could not find out how the FDA's division set-up the new sciense. I could not find any person, organisation, recommendation who/ which said: TG below 500 is OK (except E.T, pardon E.C.).

Based on facts, current practise, based on the 2 (out of 3) citied study (maybe the 3rd also, but post-an is not available yet) I could (not) imagine other final conlusion than: yes, ANCHOR is OK, since TG above 200 should be treated and Vascepa is safe, met all end-point.

(Much cheaper for any BP to BO Amarin for $15-30 than corrupt every FDA' employee :))